BD Strategy for Biologics Delivery
Sector
MedTech
Company
Emerging MedTech
Therapeutic Area
Oncology / Immunology
Treatment Modality
Drug Delivery
Product Stage
Clinical
Expertise
Partnering
An emerging medtech company developed a lymphatic drug delivery platform designed to improve the bioavailability and targeting of immuno-oncology therapies. To validate the approach, the company advanced a clinical trial in cutaneous T-cell lymphoma (CTCL) using Keytruda, evaluating whether lymphatic delivery could enhance therapeutic effect, expand response rates, and reduce systemic toxicity compared to standard intravenous administration.
Situation
An emerging medtech company developed a lymphatic drug delivery platform designed to improve the bioavailability and targeting of immuno-oncology therapies. To validate the approach, the company advanced a clinical trial in cutaneous T-cell lymphoma (CTCL) using Keytruda, evaluating whether lymphatic delivery could enhance therapeutic effect, expand response rates, and reduce systemic toxicity compared to standard intravenous administration.
Situation
Approach
We worked with the team to shape both trial strategy and business development positioning. On the clinical side, we supported design refinements to ensure endpoints captured differentiation in tumor response and immune activation, aligning with investigator and regulatory expectations. In parallel, we developed a partnering strategy that positioned the platform as a way for global pharma to extend and differentiate existing immuno-oncology franchises. Keytruda in CTCL served as a proof-of-concept use case, while signaling broader potential across oncology indications.
We worked with the team to shape both trial strategy and business development positioning. On the clinical side, we supported design refinements to ensure endpoints captured differentiation in tumor response and immune activation, aligning with investigator and regulatory expectations. In parallel, we developed a partnering strategy that positioned the platform as a way for global pharma to extend and differentiate existing immuno-oncology franchises. Keytruda in CTCL served as a proof-of-concept use case, while signaling broader potential across oncology indications.
Approach
Results
This approach strengthened the company’s ability to demonstrate the platform’s relevance in immuno-oncology and to frame its clinical results in a way that resonated with prospective partners. By linking trial outcomes to commercial differentiation, the company advanced both its clinical program and its business development strategy with large pharmaceutical stakeholders.
This approach strengthened the company’s ability to demonstrate the platform’s relevance in immuno-oncology and to frame its clinical results in a way that resonated with prospective partners. By linking trial outcomes to commercial differentiation, the company advanced both its clinical program and its business development strategy with large pharmaceutical stakeholders.
Situation
An emerging medtech company developed a lymphatic drug delivery platform designed to improve the bioavailability and targeting of immuno-oncology therapies. To validate the approach, the company advanced a clinical trial in cutaneous T-cell lymphoma (CTCL) using Keytruda, evaluating whether lymphatic delivery could enhance therapeutic effect, expand response rates, and reduce systemic toxicity compared to standard intravenous administration.
Approach
We worked with the team to shape both trial strategy and business development positioning. On the clinical side, we supported design refinements to ensure endpoints captured differentiation in tumor response and immune activation, aligning with investigator and regulatory expectations. In parallel, we developed a partnering strategy that positioned the platform as a way for global pharma to extend and differentiate existing immuno-oncology franchises. Keytruda in CTCL served as a proof-of-concept use case, while signaling broader potential across oncology indications.
Results
This approach strengthened the company’s ability to demonstrate the platform’s relevance in immuno-oncology and to frame its clinical results in a way that resonated with prospective partners. By linking trial outcomes to commercial differentiation, the company advanced both its clinical program and its business development strategy with large pharmaceutical stakeholders.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.